CardioGenics Holdings Inc · OTC:CGNH
CardioGenics — Investor Presentation (January 2012)
22 slides from CardioGenics's investor presentation, Jan 27, 2012
Slide 1: CardioGenics Inc. Investor Presentation
CardioGenics Inc. Inc INVESTOR PRESENTATION Yahia hi A. Gawad G d, MB.CH.B, MD, MSc January 2012
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS Certain statements made in this presentation that are not historical are forward forward‐looking looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward‐looking statements, with words such as "anticipate, "believe," "expec
Slide 3: Leading In Vitro Diagnostics Company
LEADING IN VITRO DIAGNOSTICS COMPANY Analyzer, y , tests and beads Lab quality results at the point of care, when time counts
Slide 4: Acute Cardiac Event
ACUTE CARDIAC EVENT Symptoms are non-diagnostic: non diagnostic: • Chest pain, shortness of breath, indigestion, heart burn, back pain, vomiting EKG changes are non‐specific Laboratory testing results determine the diagnosis 4
Slide 5: First Hour Is Golden
FIRST HOUR IS “GOLDEN” GOLDEN ASPIRIN NITROGLYCERIN ELECTROCARDIOGRAM (50% false positives) BLOOD TEST 5
Slide 6: Test Results Required in 30 Minutes
TEST RESULTS REQUIRED IN 30 MINUTES AMERICAN HEART AMERICAN COLLEGE OF ASSOCIATION CARDIOLOGY C O OG GU GUIDELINESS Source: Circulation. 1999;100:1016‐1030 6
Slide 7: 2.8 Hours Average Time for Hospital-Based Lab Results
2 8 HRS 2.8 AVERAGE TIME FOR HOSPITAL‐BASED LAB RESULTS 7
Slide 8: Cost of Incorrect Admissions
COST of INCORRECT ADMISSIONS 8M patients present with chest pain 600 000 600,000 heart attack patients diagnosed g with EKG 7 4M 7.4M patients cost lab results = MILLION PATIENTS =$31B 8
Slide 9: QL Care Analyzer: 15 Minutes, Accuracy
QL CARE™ ANALYZER 15 MINUTES ACCURACY Speed of POC of lab‐based systems 9
Slide 10: 30 Minutes or Less vs 2.8 Hours: Accuracy/Sensitivity
30 MINS OR LESS 2.8 Hrs: ACCURACY/SENSITIVITY Biosite Abbott Biomerieux Response Biomedical Beckman Coulter Dade Behring Roche Siemens BioRad I Stat I‐Stat Roche BD Ortho‐Clinical Diagnostics 10
Slide 11: Bringing Lab Accuracy to Point of Care
BRINGING LAB ACCURACY TO POINT OF CARE • Chemiluminescence • Photon‐counting of light • Solution Phase reactions • Self‐metering cartridge • No sample processing, membrane • Uses whole blood (patented) • Uses silver‐plated beads • Electronic stimulation of light • User friendly, no training required
Slide 12: Market Potential: Test Results in 15 Minutes
MARKET POTETNIAL: TEST RESULTS IN 15 MINUTES CONSUMABLES BUSINESS MODEL TROPONIN‐II TROPONIN • $650M US Market • Established reimbursement codes • $49 per test PLACE DEVICES IN ER’s PAI‐1 ‐ $300M US MARKET HFRS ‐ $1B US MARKET DISPOSABLE CARTRIDGE TESTS HFGS ‐ $400M US MARKET 200 CLINICAL IMMUNOASSA
Slide 13: Path to Market
PATH TO MARKET PILOT TESTING 510K FDA Trial 200 patients Predicate device (Siemens Centur TnI) 4 Hospitals 200 patients Wayne State University 4 sites Results expected in H1 2012 Results expected H2 2012 13
Slide 14: Pipeline
PIPELINE PRODUCT PILOT TEST 510K TEST COMMERCIAL QL CARE TM Analyzer T Troponin‐I i I F ll Follow‐on t t tests Magnetic Beads 14
Slide 15: SAVASphere Immunoassay Bead Market
IMMUNOASSAY BEAD MARKET $ billion market $1 90% of analyzers use M More sensitive 7 7x iti ththan ttop 5 commercial i lbbrands d magnetic beads 5 OEMs control 80% of market SAVASphere h TM 15
Slide 16: Revenue Ready Partnership
REVENUE READY PARTNERSHIP • Silver‐plating increases light reflectivity • Proprietary plating process • Merck Chimie: largest producer • Lower manufacturing costs of magnetic beads for IVD • $1,000/gram competitors price point • 10 year exclusive agreement • 70/30 revenue‐split • <$100/gram CGI manu
Slide 17: Financial Review
FINANCIAL REVIEW OTCBB CGNH Market Cap (1/27/12) $34.5M C h (10/31/11) Cash ~$700,000 $700 000 Shares Outstanding 55M Quarterly Burn ~$450‐600K I id Ownership Insider O hi 42% 17
Slide 18: Leadership
LEADERSHIP MANAGEMENT BOARD OF DIRECTORS Yahia A. Gawad, MB.CH.B, MD, MSc Neil Tabatznik Founder, CEO and Director Acting Chairman Jim Essex, CA Alexander Reid Chief Financial Officer Prof. Robert Roberts, MD Linda Sterling Prof. William Kostuk, MD Corporate Secretary 18
Slide 19: Upcoming News Flows
UPCOMING NEWS FLOWS • Report epo beta be a site s e testing es g data da a • Commence negotiations with distribution partners for QL Care™ Analyzer • Commercial launch of beads (SAVASphereTM) by Merck and ourselves • Evaluate beads with other major beads distributors under materials transfer agreeme
Slide 20: 15 Minutes Accuracy within the golden hour
15 MINUTES ACCURACY within the golden hour 20
Slide 21: Leading In Vitro Diagnostics Company Focused on Cardiology for the POC Market
LEADING IN VITRO DIAGNOSTICS COMPANY FOCUSED ON CARDIOLOGY FOR THE POC MARKET INVESTOR PRESENTATION Yahia hi A. Gawad G d, MB.CH.B, MD, MSc January 2012
Slide 22: Competitive Comparison - July 07, 2009
COMPETITIVE COMAPRISON ‐ JULY 07, 07 2009 CardioGenics QL Care Analyzer vs. Other Point‐of‐Care Devices and Beckman Coulter Access 2 Lab‐Based Analyzer NURSE/ DEVICE CORE SELF‐ CARTRIDGE/ CARTRIDGE WHOLE TIME FOR CARTRIDGE SAMPLE TECHNICIAN NETWORK DEVICE MANUFACTURER COST DEVICE SIZE TECHNOLOGY SEN
CardioGenics Holdings — Investor Presentation (January 2012) on 6ix